ReviewJournal of endocrinological investigation2026
Osteoporosis from the perspective of the gut-bone axis: gut microbiota, metabolites, and multi-system synergistic regulation.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeEvidence increasingly implicates the gut microbiota in skeletal homeostasis, but the mechanisms and clinical relevance of the gut-bone axis remain unclear. This narrative review aimed to synthesize evidence linking the gut microbiota and its metabolites to osteoporosis, delineate key regulatory pathways, and assess the potential of microbiota-targeted interventions.
methodsPubMed, Web of Science, and the Cochrane Library were searched through December 2025 for English-language original studies, clinical trials, and representative reviews addressing osteoporosis, the gut microbiota, microbial metabolites, probiotics, prebiotics, and fecal microbiota transplantation. After title, abstract, and full-text assessment, 125 references were included, prioritizing publications from 2020 to 2025 while retaining seminal earlier studies.
resultsPreclinical and human evidence supports an association between gut microbial dysbiosis and altered bone homeostasis, particularly in postmenopausal osteoporosis. However, human evidence remains predominantly cross-sectional, taxonomic findings vary across cohorts, and data in men are scarce. Short-chain fatty acids, secondary bile acids, tryptophan-derived metabolites, and bacterial extracellular vesicles may regulate bone remodeling directly and through immune modulation, endocrine signaling, intestinal barrier integrity, and nutrient absorption. Findings for probiotics and prebiotics are strain-, substrate-, and population-dependent: some clinical studies report improvements in bone mineral density or turnover markers, whereas others show no significant benefit. Evidence for fecal microbiota transplantation remains preclinical.
conclusionThe gut-bone axis provides a plausible framework for understanding osteoporosis and may offer adjunctive therapeutic targets. Clinical translation requires adequately powered longitudinal studies and randomized trials incorporating etiological and sex-based stratification, functional multi-omics, and clinically meaningful skeletal outcomes.
Indexed as
Identifiers
42635907What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.